NEW YORK — Biotechnology company Celgene said today it is expanding its array of cancer treatments with a deal to buy Abraxis BioScience for $2.9 billion in cash and stock.

Celgene said the transaction could add $1 billion to its annual sales by 2015.

Abraxis Bioscience is based in Los Angeles and it makes the injectable cancer drug Abraxane. Abraxane is approved as a treatment for breast cancer and is being tested against skin, lung, and pancreatic cancer. If Abraxane is approved for those other uses, the value of the deal could rise to more than $3.55 billion.

Celgene's top seller is Revlimid, which is approved to treat the blood cancer multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia.

ST. LOUIS — Boeing says it has agreed to acquire combat engineering firm Argon ST for about $775 million in cash in a deal to expand its capabilities in intelligence gathering and warfare.Argon ST is a Fairfax, Va., company that develops a variety of systems used in surveillance, reconnaissance and combat.Boeing's offer of $34.50 per share is a 41 percent premium to Argon's closing price on Tuesday. Argon says its board has approved it and plans to recommend it to shareholders.The deal is expected to close in the third quarter.